As­traZeneca's COPD triple ther­a­py slammed by CRL — falling fur­ther be­hind GSK

Days af­ter tout­ing key ad­vances for its on­col­o­gy strat­e­gy, As­traZeneca is be­ing slapped by a reg­u­la­tor set­back in the res­pi­ra­to­ry space.

The FDA has re­fused to ap­prove PT010, a much-tout­ed triple-drug com­bi­na­tion for chron­ic ob­struc­tive pul­monary dis­ease that it had hoped would chal­lenge Glax­o­SmithK­line. The com­plete re­sponse let­ter fol­lowed an OK in Japan sev­er­al months ago, push­ing the drug on­to the mar­ket as Breztri Aeros­phere.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER